Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease

Part of paid clinical trials in Stanford, California.

Sponsor
Stanford University
Study ID
NCT00388349
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Gemcitabine — DRUG
  • Vinorelbine — DRUG
  • Carmustine — DRUG
  • Etoposide — DRUG
  • Cyclophosphamide — DRUG
  • Autologous HCT — PROCEDURE

Study Details

This is a phase 2 study of gemcitabine + high-dose chemotherapy followed by peripheral blood stem cell (PBSC) rescue for Hodgkin's Disease

Key Dates

Start date
Sep 30, 2001
Status verified
May 2017
Primary completion
Mar 31, 2008
Completion
Sep 30, 2010

Study Design

Enrollment
146 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Gemcitabine + Autologous HCT
    Gemcitabine and high-dose chemotherapy followed by peripheral blood stem cell (PBSC) rescue. Chemotherapy includes Gemcitabine + Vinorelbine + Carmustine + Etoposide + Cyclophosphamide.

Primary Outcome Measure

Dose-limiting Toxicity of Gemcitabine Due to Non-hematologic Toxicity [ Time Frame: 6 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Stanford University School of MedicineStanfordCalifornia94305-

Find similar trials in Stanford, CA

By research site
Stanford University School of Medicine· Stanford, CA

Related Studies